Literature DB >> 33085794

Factor H-related protein 1: a complement regulatory protein and guardian of necrotic-type surfaces.

Christine Skerka1, Gabriele Pradel2, Luke D Halder1, Peter F Zipfel1, Svante L H Zipfel3, Olaf Strauß4.   

Abstract

Factor H-related protein 1 (FHR-1) is a member of the factor H protein family, which is involved in regulating innate immune complement reactions. Genetic modification of the encoding gene, CFHR1 on human chromosome 1, is involved in diseases such as age-related macular degeneration, C3 glomerulopathy and atypical haemolytic uraemic syndrome, indicating an important role for FHR-1 in human health. Recent research data demonstrate that FHR-1 levels increase in IgA nephropathy and anti-neutrophilic cytoplasmic autoantibodies (ANCA) vasculitis and that FHR-1 induces strong inflammation in monocytes on necrotic-type surfaces, suggesting a complement-independent role. These new results increase our knowledge about the role of this complement protein in pathology and provide a new therapeutic target, particularly in the context of inflammatory diseases induced by necrosis. This review summarizes current knowledge about FHR-1 and discusses its role in complement reactions and inflammation. LINKED ARTICLES: This article is part of a themed issue on Canonical and non-canonical functions of the complement system in health and disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.14/issuetoc.
© 2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Entities:  

Keywords:  complement; factor H-related protein 1; inflammation

Mesh:

Substances:

Year:  2020        PMID: 33085794     DOI: 10.1111/bph.15290

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  1 in total

1.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.

Authors:  Robert Fredriksson; Malin C Lagerström; Lars-Gustav Lundin; Helgi B Schiöth
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

  1 in total
  5 in total

1.  Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces.

Authors:  Arthur Dopler; Selina Stibitzky; Rachel Hevey; Marco Mannes; Mara Guariento; Britta Höchsmann; Hubert Schrezenmeier; Daniel Ricklin; Christoph Q Schmidt
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

2.  Factor H-related protein 1 (FHR-1) is associated with atherosclerotic cardiovascular disease.

Authors:  Sarah Irmscher; Svante L H Zipfel; Luke D Halder; Lia Ivanov; Andres Gonzalez-Delgado; Christoph Waldeyer; Moritz Seiffert; Fabian J Brunner; Monika von der Heide; Ina Löschmann; Sonia Wulf; Darina Czamara; Nikolina Papac-Milicevic; Olaf Strauß; Stefan Lorkowski; Hermann Reichenspurner; Michael V Holers; Nirmal K Banda; Tania Zeller; Elisabeth B Binder; Christoph J Binder; Thorsten Wiech; Peter F Zipfel; Christine Skerka
Journal:  Sci Rep       Date:  2021-11-18       Impact factor: 4.379

3.  A synthetic protein as efficient multitarget regulator against complement over-activation.

Authors:  Natalia Ruiz-Molina; Juliana Parsons; Madeleine Müller; Sebastian N W Hoernstein; Lennard L Bohlender; Steffen Pumple; Peter F Zipfel; Karsten Häffner; Ralf Reski; Eva L Decker
Journal:  Commun Biol       Date:  2022-02-22

4.  Atypical Hemolytic Uremic Syndrome-Associated FHR1 Isoform FHR1*B Enhances Complement Activation and Inflammation.

Authors:  Boyang Xu; Yuqi Kang; Yujing Du; Weiyi Guo; Li Zhu; Hong Zhang
Journal:  Front Immunol       Date:  2022-01-21       Impact factor: 7.561

5.  A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce.

Authors:  Krzysztof Laudanski; Tony Okeke; Kumal Siddiq; Jihane Hajj; Mariana Restrepo; Damodar Gullipalli; Wen-Chao Song
Journal:  Sci Rep       Date:  2022-08-11       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.